230 related articles for article (PubMed ID: 16925104)
1. Management of anemia in patients with hematologic malignancies.
Straus DJ
Oncology (Williston Park); 2006 Jul; 20(8 Suppl 6):8-11. PubMed ID: 16925104
[TBL] [Abstract][Full Text] [Related]
2. Epoetin alfa corrects anemia and improves quality of life in patients with hematologic malignancies receiving non-platinum chemotherapy.
Littlewood TJ; Nortier J; Rapoport B; Pawlicki M; de Wasch G; Vercammen E; Schuette W; Wils J; Freund M;
Hematol Oncol; 2003 Dec; 21(4):169-80. PubMed ID: 14735555
[TBL] [Abstract][Full Text] [Related]
3. Benefits of early intervention with erythropoiesis- stimulating proteins in chemotherapy-induced anemia.
Lyman GH
Oncology (Williston Park); 2006 Jul; 20(8 Suppl 6):16-20. PubMed ID: 16925106
[TBL] [Abstract][Full Text] [Related]
4. Quality-of-life and health benefits of early treatment of mild anemia: a randomized trial of epoetin alfa in patients receiving chemotherapy for hematologic malignancies.
Straus DJ; Testa MA; Sarokhan BJ; Czuczman MS; Tulpule A; Turner RR; Riggs SA
Cancer; 2006 Oct; 107(8):1909-17. PubMed ID: 16977654
[TBL] [Abstract][Full Text] [Related]
5. Optimizing the dose and schedule of darbepoetin alfa in patients with chemotherapy-induced anemia.
Glaspy J
Oncology (Williston Park); 2006 Jul; 20(8 Suppl 6):29-32. PubMed ID: 16925109
[TBL] [Abstract][Full Text] [Related]
6. A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer.
Schwartzberg LS; Yee LK; Senecal FM; Charu V; Tomita D; Wallace J; Rossi G
Oncologist; 2004; 9(6):696-707. PubMed ID: 15561813
[TBL] [Abstract][Full Text] [Related]
7. Epoetin alfa therapy for patients with hematologic malignancies and mild anemia.
Straus DJ
Clin Lymphoma; 2003 Aug; 4 Suppl 1():S13-7. PubMed ID: 14556671
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of darbepoetin alfa versus epoetin alfa for the treatment of chemotherapy induced anemia in patients with gynecologic malignancies.
Case AS; Rocconi RP; Kilgore LC; Barnes MN
Gynecol Oncol; 2006 Jun; 101(3):499-502. PubMed ID: 16406064
[TBL] [Abstract][Full Text] [Related]
9. Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.
Voravud N; Sriuranpong V; Suwanrusme H
J Med Assoc Thai; 2007 Jun; 90(6):1082-8. PubMed ID: 17624200
[TBL] [Abstract][Full Text] [Related]
10. Phase III clinical trials with darbepoetin: implications for clinicians.
Glaspy J
Best Pract Res Clin Haematol; 2005; 18(3):407-16. PubMed ID: 15792914
[TBL] [Abstract][Full Text] [Related]
11. Darbepoetin alfa: potential role in managing anemia in cancer patients.
Pirker R; Smith R
Expert Rev Anticancer Ther; 2002 Aug; 2(4):377-84. PubMed ID: 12647980
[TBL] [Abstract][Full Text] [Related]
12. Retrospective observational study of patients with chemotherapy-related anemia receiving erythropoietic agents.
Mark TL; McKenzie RS; Fastenau J; Piech CT
Curr Med Res Opin; 2005 Sep; 21(9):1347-54. PubMed ID: 16197652
[TBL] [Abstract][Full Text] [Related]
13. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients.
Nissenson AR; Swan SK; Lindberg JS; Soroka SD; Beatey R; Wang C; Picarello N; McDermott-Vitak A; Maroni BJ
Am J Kidney Dis; 2002 Jul; 40(1):110-8. PubMed ID: 12087568
[TBL] [Abstract][Full Text] [Related]
14. Erythropoietic agents in anaemic patients with cancer: a retrospective observational survey of epoetin alpha, epoetin beta and darbepoetin alpha use in routine clinical practice.
Pujade-Lauraine E; Richard AJ; Sapède C; Hayward C
Oncol Rep; 2005 Oct; 14(4):1037-44. PubMed ID: 16142369
[TBL] [Abstract][Full Text] [Related]
15. Optimizing the treatment of anemia in cancer patients. The role of a new erythropoietic agent.
Henry DH
Oncology (Williston Park); 2002 Oct; 16(10 Suppl 11):9-12. PubMed ID: 12435168
[TBL] [Abstract][Full Text] [Related]
16. Darbepoetin alfa for the treatment of cancer-related anemia: an update.
Pirker R
Expert Rev Anticancer Ther; 2004 Oct; 4(5):735-44. PubMed ID: 15485310
[TBL] [Abstract][Full Text] [Related]
17. Epoetin alfa versus darbepoetin alfa in chemotherapy-related anemia.
Cersosimo RJ; Jacobson DR
Ann Pharmacother; 2006 Jan; 40(1):58-65; quiz 169-70. PubMed ID: 16332942
[TBL] [Abstract][Full Text] [Related]
18. Epoetin alfa as a supportive measure in hematologic malignancies.
Straus DJ
Semin Hematol; 2002 Oct; 39(4 Suppl 3):25-31. PubMed ID: 12447849
[TBL] [Abstract][Full Text] [Related]
19. Darbepoetin alpha coming of age.
Pedrazzoli P; Cinieri S; Lorusso V; Gamucci T; Secondino S; Silvestris N
Anticancer Res; 2007; 27(6C):4419-24. PubMed ID: 18214054
[TBL] [Abstract][Full Text] [Related]
20. Anemia in cancer patients: significance, epidemiology, and current therapy.
Tchekmedyian NS
Oncology (Williston Park); 2002 Sep; 16(9 Suppl 10):17-24. PubMed ID: 12380951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]